Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and ...

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved ...

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; ...

Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib Priority Review granted following FDA acceptance of ...

The winners of the Elsevier Foundation Chemistry for Climate Action Challenge have been announced at the 10th Green & Sustainable Chemistry Conference in Dresden, Germany. The two winning projects ...

Catching pancreatic cancer early can increase the five-year survival rate from 15% to 80%. Patients with pancreatic cysts, ...

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to ...

COLUMBIA, S.C (WCIV) — South Carolina lawmakers have approved legislation that would ban 'grade-floor' policies in K-12 public schools, positioning the Palmetto State to be the first in the nation to ...

NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30, 20 ...

Be sure to catch Open House: Temple Shir Tikvah on the Woburn Patch calendar ...

A systematic review finds that diagnostic discordance in bone and soft tissue sarcoma may reduce survival, supporting expert second opinions. Phase 2 trial results show anlotinib with anthracyclines ...

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...